The Complete Brown County Guide to Rick Simpson Oil: OilWell Cannabis’s Modern RSO Formulas

Here in Brown County—where the rolling hills of our state park meet the galleries of Nashville’s Artist Colony, where Hoosier resilience runs deep but healthcare access can feel miles away—we understand what it means to seek alternatives when conventional medicine falls short. Whether you’re a veteran in Helmsburg grappling with PTSD, a retiree in Gnaw Bone managing chronic pain, or a cancer patient facing the long drive to IU Health Simon Cancer Center in Indianapolis, you’ve likely heard whispers about Rick Simpson Oil. Maybe you’ve seen it discussed in online support groups, or heard about it at the VFW hall in Nashville. Maybe you’re simply looking for honest answers about what RSO actually is, what it can and cannot do, and whether it’s legal to access here in southern Indiana.

We wrote this guide for you. OilWell Cannabis is a Houston-based company founded on the belief that people deserve transparent, evidence-based information about cannabinoids—not hype, not snake oil, but real science presented honestly. We ship our Farm Bill-compliant RSO formulas nationwide, including right here to Brown County, because we believe geography shouldn’t determine access to potentially life-changing medicine. This isn’t about replacing your oncologist at Brown County Hospital or your pain specialist in Bloomington—it’s about giving you the knowledge to make informed decisions alongside your healthcare team.

Who is Rick Simpson? The Man Behind the Oil, Not the Myth

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He wasn’t a doctor, scientist, or researcher—he was a power engineer and maintenance worker, a blue-collar tradesman whose path into cannabis advocacy began when the medical system failed him. In 1997, while working at a hospital in Moncton, New Brunswick, he fell from scaffolding and suffered a serious head injury. The aftermath left him with persistent tinnitus, dizziness, and post-concussion symptoms that conventional medications either failed to help or made worse. When he asked his physician about cannabis, the request was refused. Sound familiar? Many here in Brown County have faced similar dismissal when asking local doctors about cannabis alternatives.

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health at the Medical College of Virginia, where THC reportedly slowed or shrank tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference for Simpson, even though its findings were never replicated in controlled human cancer trials.

The pivotal moment came in 2003. Three bumps on his arm were diagnosed as basal cell carcinoma. Rather than pursue conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. Important context: No independent medical verification of this outcome has ever been published. No biopsy confirmation or clinical follow-up appears in any peer-reviewed source. Simpson’s account is personal testimony, not medical evidence—but it became the origin story of Rick Simpson Oil and the catalyst for a global movement.

The Traditional RSO Protocol: Simpson’s 60-Gram, 90-Day Regimen

Simpson’s core treatment recommendation was a structured oral protocol: consume 60 grams of concentrated cannabis oil over approximately 90 days. He described this as a cancer treatment, though he also recommended it for numerous other conditions. Here is the complete protocol as Simpson documented it:

Goal: Consume 60 grams of high-THC cannabis oil over roughly 90 days.

Titration Schedule:

• Week 1: Begin with a dose the size of half a grain of dry rice (approximately 10-15 mg of oil) taken three times daily—morning, afternoon, and before bed. Total daily intake: 30-45 mg.
• Weeks 2-5: Double the dose every four days. By the end of four to five weeks, reach approximately 1 gram (1,000 mg) of oil per day, divided into three equal doses.
• Weeks 5-12: Maintain 1 gram per day, divided into three doses of roughly 333 mg each, until all 60 grams are consumed.

Administration Methods:

• Primary: Oral—place dose under the tongue (sublingual) or swallow. Simpson considered this essential for systemic absorption and internal cancers.
• Secondary: Topical—apply directly to skin cancers or lesions, cover with a bandage, change every 3-4 days. He combined topical with oral for skin cancers.
• Not recommended: Inhalation—he acknowledged vaporizing for immediate symptom relief but maintained oral dosing was necessary for sustained therapeutic exposure.

Tolerance and Psychoactive Effects:

• Simpson claimed patients develop THC tolerance within 3-4 weeks.
• He considered euphoria, sedation, or disorientation a minor, temporary side effect.
• Recommended initial doses at night to sleep through peak effects.
• Warned against driving or operating machinery during titration.

Post-Protocol Maintenance: After completing 60 grams, Simpson recommended 1-2 grams per month indefinitely for long-term health and cancer prevention.

Dietary Recommendations: He advocated reducing sugar and processed foods, though this was secondary to the oil protocol.

Critical Context for Brown County Readers: This protocol was designed around crude, unstandardized material with no controlled trial validation. At peak dosing, patients consumed roughly 600-900 mg of delta-9 THC daily—a dose far exceeding anything studied clinically. The FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 mg per day. Consuming 600-900 mg daily carries serious risks: severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. For cancer patients—who are medically complex—using unregulated oil as primary treatment introduces harm beyond the oil itself.

What Traditional RSO Actually Was: The Unvarnished Truth

Traditional RSO refers to a specific type of oil Simpson made. Understanding what it was helps you evaluate what’s sold today in Indiana markets.

Source Material: Single high-THC, indica-dominant cannabis strains. No standardization—material varied by availability and season.

Extraction Solvent: Originally naphtha (petroleum-based lighter fluid) or 99% isopropyl alcohol. Neither is food-grade. Naphtha may contain benzene, toluene, and other carcinogens.

Extraction Process:

1. Dry cannabis in a bucket
2. Cover with solvent, agitate 3-4 minutes
3. Pour through filter into collection vessel
4. Repeat with fresh solvent
5. Evaporate solvent in rice cooker at low heat
6. Transfer thick, dark oil to syringes

Appearance: Nearly black, thick, tar-like, sticky oil with strong cannabis odor and possible solvent-residual smell.

Cannabinoid Profile: Fully decarboxylated, THC-dominant (60-90% estimated), with minor cannabinoids at natural, uncontrolled ratios. No lab verification.

Terpenes: Minimal to none. High-heat evaporation destroyed terpenes.

Standardization: None. Every batch differed based on plant material, solvent, technique.

Residual Solvent Risk: Incomplete purging leaves potentially harmful residues. Without lab testing, impossible to verify safety.

Simpson’s Claims vs. The Evidence: What We Know and Don’t Know

Simpson claimed RSO could cure cancer and treat diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, and more. Let’s evaluate these against actual evidence.

What Simpson Was Not: Not a scientist, physician, pharmacologist, or researcher. No formal medical training. Never designed, conducted, or published a clinical trial. His evidence base: personal experience and unverified testimonials.

What Preclinical Literature Shows: In vitro and animal studies demonstrate THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines. Animal models show some tumor-growth inhibition. These findings generate legitimate scientific interest but have not translated into proven human cancer cures.

What Preclinical Literature Does NOT Show: No human clinical trial has demonstrated RSO or any cannabis oil cures cancer. Small human trials in glioblastoma have been exploratory and inconclusive.

Institutional Positions:

• National Cancer Institute (NCI): Acknowledges cannabinoid anticancer research in labs and animals but does not endorse cannabis as cancer treatment.
• FDA: Has not approved any cannabis plant product for cancer. Only purified CBD (Epidiolex for seizures) and synthetic THC analogues (dronabinol/nabilone for chemo nausea and AIDS wasting) are approved.
• Health Canada: Never approved RSO or cannabis oil as cancer cure.
• NCCIH: Strongest evidence is for rare epilepsies, chemo nausea/vomiting, and HIV/AIDS appetite—not cancer cure.

What Simpson Got Right: He drew attention to cannabinoids as serious biomedical research when the world ignored them. His advocacy helped create conditions for today’s legal cannabis industry and research infrastructure. The term “RSO” remains the most recognized name for full-spectrum cannabis extract.

What He Overstated: The leap from preclinical signals to cancer cure was never supported by human evidence. Encouraging patients—especially cancer patients—to rely on RSO instead of proven therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed treatment for treatable cancers is a documented concern.

The Legacy: Why “RSO” Means So Many Different Things Today

The term RSO has become generic. Walk into a shop in Indianapolis or browse online, and “RSO” can mean almost any full-spectrum extract in a syringe—regardless of extraction method, cannabinoid profile, or quality. Many products bear little resemblance to what Simpson made.

Simpson himself has criticized commercial products using the RSO name while departing from his original method and philosophy. He believed in free access and DIY production. The commercialization of cannabis oil created a philosophical tension: is this evolution (quality control, testing, precision) or betrayal (profit, gatekeeping)? The cannabis community remains divided.

One thing is certain: modern RSO has evolved substantially, and those changes matter for patients here in Brown County.

Traditional RSO vs. Modern Formulated RSO: Side-by-Side

Why OilWell’s Formulas Diverge From Traditional RSO

Our approach is informed by Simpson’s tradition but departs deliberately:

Multi-Cannabinoid Approach: Traditional RSO used whatever single strain was available. Our formula includes seven cannabinoids—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—because the entourage-effect literature suggests benefit from diversity, even while clinical proof of whole-formula synergy remains limited [20][29].

Terpene Preservation: Traditional RSO had no terpenes. We include live terpenes at 5% with a defined profile (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene) because terpene bioactivity is plausible at preclinical levels [20]-[28].

THCa as Separate Ingredient: Traditional RSO fully decarboxylated everything. We preserve THCa at 1,500mg because its evidence profile suggests anti-inflammatory and neuroprotective potential that is lost when it converts to THC [12].

Reduced Delta-9 THC Dominance: Traditional RSO was 60-90% delta-9 THC. Our sublingual formula uses only 90mg delta-9 THC total, distributing the remaining cannabinoid content across CBD (4,500mg), CBG (3,000mg), delta-8 THC (6,000mg), CBN (750mg), and CBC (750mg)—a broader pharmacologic profile.

Product Format Innovation: Simpson envisioned only oral oil. We offer both a 30mL sublingual oil and a 1-gram vape cartridge, acknowledging that different delivery routes have different pharmacokinetic profiles [14].

Solvent Safety: Why Brown County Should Care

Traditional RSO production used naphtha or isopropyl alcohol—neither food-grade. Naphtha, a petroleum hydrocarbon mixture, may contain benzene, toluene, and other carcinogens. Incomplete purging is difficult to verify without lab testing.

Modern extraction uses food-grade ethanol or supercritical CO₂, allowing complete solvent removal validated by analytical methods like headspace gas chromatography. This is one of the most straightforward safety improvements over traditional RSO.

OilWell’s RSO isn’t an extraction product—it’s a formulated blend of individual cannabinoid distillates and isolates combined in a controlled environment. No solvents in the finished product. We use organic MCT oil as the carrier, providing neutral taste and better absorption than traditional tar-like RSO.

Third-party lab testing covers potency, terpenes, pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis are available on request and through our website—transparency that matters when you’re trusting a product with your health.

The Decarboxylation Choice: Why It Matters for Brown County

Traditional RSO was always fully decarboxylated—every THCa molecule converted to psychoactive THC. You had no choice about impairment.

Our sublingual formula contains 1,500mg THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1: Raw, No Heat
All 1,500mg stays as THCa—completely non-psychoactive. Evidence suggests anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. Perfect for daytime use, work, driving, or any situation requiring zero impairment. For Brown County residents who operate farm equipment, work at the hospital in Nashville, or simply need functional relief, this is game-changing.

Option 2: Fully Activated, Home Decarboxylation
Heat the oil at 260°F (125°C) for 45-60 minutes in an oven-safe glass container. This converts 1,500mg THCa into approximately 1,315mg delta-9 THC. Combined with the existing 90mg delta-9 THC, you get ~1,405mg total delta-9 THC plus 6,000mg delta-8 THC—psychoactive potency comparable to traditional illegal RSO, entirely at your discretion. The conversion ratio: 1mg THCa = 0.877mg delta-9 THC after decarboxylation (reflecting CO₂ molecule loss).

Option 3: Vape, Auto-Decarboxylation
Our RSO Vape Cartridge vaporizes at 400-450°F, instantly converting THCa to delta-9 THC with each puff. Fastest-onset delivery method—1-2 minutes.

This design puts potency control in your hands, aligning with Simpson’s principle that patients should control their medicine, but implementing it through actual chemistry rather than rhetoric.

Legal Framework for Brown County, Indiana: What You Need to Know

Here’s where we get real about Indiana law—a topic most companies avoid.

Federal Law: The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3% delta-9 THC by dry weight. This is our foundation.

Indiana State Law: Indiana has no medical or recreational cannabis program. However, the state has not explicitly banned Farm Bill-compliant hemp products. Our RSO Sublingual Oil contains only 90mg delta-9 THC in the entire 30mL bottle—3mg/mL—well under the 0.3% threshold. All cannabinoids are hemp-derived. This product is legal under federal law and in Indiana.

THCa Legal Status: THCa is the acidic precursor to delta-9 THC. At point of sale, it’s not delta-9 THC, making it Farm Bill compliant. You can legally purchase, possess, and transport our product in Brown County, Indiana.

Important Legal Notice: THCa converts to delta-9 THC when heated. If you choose to decarboxylate at home, you become responsible for understanding local laws regarding activated THC. We ship with full documentation, COAs, and receipts to demonstrate Farm Bill compliance at purchase. The product contains less than 0.3% delta-9 THC as required by law. Buyer assumes responsibility for any conversion decisions. Void where prohibited by law.

Open-Source Formulas: Our Promise to Brown County

Rick Simpson gave his oil away for free and taught people how to make it. He never patented his method. OilWell adapted that ethos for the modern marketplace: we sell a professionally manufactured, lab-tested product, and we publish the complete recipe for those who want to make their own.

If you can’t afford $129.99 for our sublingual oil, you can source the individual cannabinoid distillates and make your own version using the exact formula below. This isn’t marketing—it’s our character.

The Bentley Connection: Before publishing RSO formulas, we shared the CBD golden paste recipe that saved Bentley’s life. That same recipe is published on our About Us page, so any Brown County pet owner facing a similar crisis can make it themselves:

CBD Golden Paste Recipe for Pets:

• ½ cup organic turmeric powder
• 1 cup water
• ⅓ cup unrefined organic coconut oil
• 1-2 tsp freshly ground black pepper (for absorption)
• CBD oil (dose per pet size; consult veterinarian)

Instructions: Mix turmeric and water in saucepan over low heat, stirring continuously for 7-10 minutes until thick paste forms. Add coconut oil and pepper. Cool, store in refrigerator up to 2 weeks. Mix with pet’s food 1-2x daily.

This pattern—publishing what works, whether people buy from us or not—demonstrates that our open-source philosophy is foundational behavior, not strategy.

The OilWell RSO Sublingual Oil Formula: Complete Transparency

Here is our complete, open-source formula. Every milligram is published.

Additional Specifications:

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Carrier: Organic MCT oil
• Bottle Size: 30mL (1 fl oz)
• Concentration: 553mg active cannabinoids per mL
• Delta-9 THC: 3mg/mL (0.3% by weight—Farm Bill compliant)
• Dosing: Graduated dropper with 0.1mL increments
• Onset: 15-45 minutes (sublingual)
• Peak: 1-2 hours
• Duration: 4-6 hours
• Bioavailability: 13-19%
• Doses per Bottle: 40-60 depending on serving size

For Brown County residents calculating cost-per-milligram: at $129.99 for 16,590mg total cannabinoids, you’re paying approximately $0.0078 per mg—highly competitive compared to Indiana dispensary prices, if Indiana had dispensaries.

The OilWell RSO Vape Cartridge Formula

Our vape formula uses percentages for the 1-gram cartridge format:

Additional Specifications:

• Live Terpenes: 5%+
• Thread: 510 universal battery compatibility
• Total Cannabinoids: 900mg+
• Onset: 1-2 minutes (fastest available)
• Peak: 10-15 minutes
• Duration: 2-4 hours
• Bioavailability: 10-35%
• Auto-Decarboxylation: THCa converts to delta-9 THC at 400-450°F vaping temperature

Price: $49.99 per 1-gram cartridge

Terpene Profile: The Aroma of Science

Both products share the same seven-terpene profile, selected for complementary effects:

• Limonene: Citrus-bright notes, potential mood elevation [20]-[22]
• Myrcene: Herbal depth, relaxation potential [20][23]
• Caryophyllene: Pepper/spice, CB2 receptor agonist [24]
• Pinene: Forest-fresh, clarity potential [20][25]
• Linalool: Floral lavender, calm potential [20][22][25][26]
• Humulene: Earthy/woody, anti-inflammatory interest [20][27]
• Terpinolene: Piney/fruity complexity [20][28]

For Brown County residents who know the smell of pine forests in Yellowwood State Forest or the citrus brightness of local farmers’ markets, these terpenes connect the product to familiar sensory experiences while delivering potential therapeutic effects.

When to Use Each Format: Practical Guidance for Brown County

Brown County Application Example: You’re attending the Brown County Apple Festival in Nashville but dealing with chronic back pain from years of farm work. Take 0.3mL raw sublingual before leaving—anti-inflammatory benefits without impairment. That evening, decarboxylate 0.5mL for full-potency relief while you sleep.

Competitive Comparison: OilWell vs. What’s Available to Brown County

OilWell RSO vs. Traditional RSO (Black Market)

OilWell RSO vs. Indiana CBD Products

Most CBD products sold at Nashville’s health stores or Bloomington vape shops contain only CBD isolate or broad-spectrum hemp oil at 1,000mg total cannabinoids for $40-50. OilWell’s sublingual oil delivers 16,590mg total cannabinoids across seven compounds, including psychoactive options, for $129.99. That’s 16x the cannabinoid content with vastly broader therapeutic potential.

Condition-Specific Usage Context for Brown County Residents

Critical Disclaimer: These contexts are informed by cannabinoid research cited in our GENERAL KNOWLEDGE section. They are not medical prescriptions, not FDA-approved, and not substitutes for professional care. Always consult your healthcare provider, especially if receiving treatment at Brown County Hospital or IU Health Bloomington. Do not operate vehicles or machinery while under psychoactive cannabinoid influence.

Chemotherapy-Related Nausea & Appetite Support:

• Pre-chemo: 0.5-1.0mL sublingual approximately 1 hour before treatment
• Breakthrough nausea: 2-3 vape puffs for immediate relief
• Post-chemo: 0.5mL sublingual every 6 hours as needed
• Sleep support: 1.0-2.0mL sublingual before bed (delivers 25-50mg CBN)
• Evidence: Delta-8 antiemetic [9], delta-9 nausea control [1][13], CBD anxiety buffering [3]

Chronic Pain (Arthritis, Fibromyalgia, Neuropathy):

• Daytime: 0.3-0.5mL raw sublingual—anti-inflammatory without impairment
• Nighttime: 0.5-1.0mL decarboxylated sublingual—pain relief + CBN sleep support
• Breakthrough: Vape as needed for rapid onset
• Evidence: CBD pain [4], delta-9 pain [13], caryophyllene CB2 activation [24], THCa COX-2 inhibition [12]

Sleep Disorders (Insomnia, Poor Sleep Architecture):

• Before bed: 1.0-2.0mL sublingual
• At 2.0mL: 50mg CBN—the dosage studied in 2024 sleep literature [16][17]
• At 1.0mL: 25mg CBN—above threshold associated with reduced sleep disturbance
• Evidence: CBN sleep studies [16][17], cannabis sleep review literature

Anxiety & Stress (PTSD, Generalized Anxiety):

• Daytime functional: 0.3mL raw sublingual—CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0mL sublingual—full profile including CBN for sleep architecture
• Evidence: CBD anxiety [3], CBG pharmacology [7][8], limonene entourage effect [20]

General Titration Principle: Start low, go slow. Begin with 0.25-0.5mL sublingual and assess effects over 2-3 hours before increasing. Individual responses vary by weight, metabolism, tolerance, and concurrent medications (especially important for Brown County residents on multiple prescriptions).

Delivery to Brown County: Getting Your RSO

We understand that living in rural Indiana means driving 30+ minutes for many services. That’s why we’ve built a delivery system that brings RSO directly to your door.

Nationwide Shipping to Brown County:

• USPS Priority Mail: 2-3 business days to Nashville, Helmsburg, Gnaw Bone, or anywhere in Brown County
• FedEx/UPS Ground: 3-5 business days with tracking
• Discreet Packaging: No cannabis branding visible—plain box for privacy
• Temperature-Stable: Special packaging for Indiana summers
• Signature Option: Available for security
• COAs Included: Full lab documentation for your records

How to Order:

1. Visit oilwellcbd.com
2. Select RSO Sublingual Oil ($129.99) or Vape Cartridge ($49.99)
3. Enter your Brown County address
4. Choose shipping method
5. Complete age verification (21+)
6. Track your package

International Shipping: While most Brown County residents won’t need this, we ship globally with complete customs documentation for customers who verify local legality. The THCa legal framework makes this possible—something Rick Simpson could never do when his oil was Schedule I everywhere.

How Our Formulas Connect to the Evidence

Every cannabinoid and terpene in our formula has its evidence profile in our GENERAL KNOWLEDGE section (see below). We apply the same evidence standards to our products that we apply to the broader field. Where evidence is strong (CBD for seizures, delta-9 THC for chemo nausea), we say so confidently. Where it’s emerging (CBG for neuroprotection, CBC for neurogenesis), we say so honestly. Where it’s weak (CBN for sleep), we acknowledge the gap.

We don’t exempt ourselves from the evidence hierarchy. That is intentional. As Colin said in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

About OilWell Cannabis: The Story Behind the Formula

OilWell Cannabis was founded by Colin Valencia in Houston, Texas. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen has vibrant culture but limited opportunities outside retail and healthcare. Reynosa is an industrial hub plagued by cartel violence.

Colin’s childhood involved early exposure to these complexities. By sixteen, after seeing friends killed or imprisoned, he had to leave home. Despite the dangers, he didn’t fall into selling harder substances. He focused on cannabis, seeing it as safer and more beneficial. He learned the plant intimately while operating in the shadows, then transitioned to legal business.

Later, Colin became a formally trained software engineer, doing custom development for Baylor College of Medicine in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines OilWell’s approach.

But the real origin story begins with a dog named Bentley.

Bentley’s Story: The Miracle That Started Everything

Bentley was more than a pet—he was family. When he fell seriously ill, veterinarians delivered the verdict: euthanasia was the only option. Bentley was paralyzed in his back legs. Pain medications would destroy his internal organs, causing more suffering.

Giving up wasn’t an option. In a desperate search for alternatives, a rescue worker named Jessica asked Colin: “You’ve moved how many tons of weed and you’ve never heard of CBD?” That question exposed a blind spot that became a mission.

Colin created CBD golden paste—a specialized cannabinoid formula for pets. It wasn’t a cure, but it was hope. And that hope delivered the impossible: Bentley got up, walked over to Colin, and brought him his ball. From paralyzed and facing euthanasia to playing fetch. This was not placebo—dogs don’t respond to placebo. This was cannabinoid medicine succeeding where pharmaceuticals failed.

Bentley lived another ten years, dying naturally at age twenty. During those years, Colin developed formulas for every age-related condition Bentley faced:

• Neurodegeneration → CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection
• Dementia → CBC’s role in neurogenesis
• Glaucoma → THC’s CB1 agonism for intraocular pressure reduction
• Crippling arthritis → Multi-pathway anti-inflammatory approach using CBD, CBG, THCa, and beta-caryophyllene

Single cannabinoids weren’t enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Precision mattered—Bentley’s life depended on formula accuracy.

Colin’s Personal Journey: From Patient to Provider

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—using the cannabinoid knowledge he developed keeping Bentley alive.

The Peace Gummies formula was created during midnight experiments while fighting benzo withdrawal. Colin personally uses the vape form to manage his insomnia and severe PTSD. This is not theoretical knowledge—he lived what RSO patients live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills don’t.

The OilWell Philosophy: Four Core Principles

OilWell’s RSO is not traditional RSO. It’s a formulated, multi-cannabinoid product informed by tradition but solving problems that limited Simpson’s original vision.

1. Accessibility Over Gatekeeping
   No medical card required. Anyone 21+ can purchase. We ship nationwide, including to Brown County. Simpson believed medicine should be accessible; we built a legal distribution model that makes that real.

2. Patient-Controlled Potency
   THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw or decarboxylate it into delta-9 THC. Simpson believed patients should control their medicine; we engineered a product that puts that control in your hands through chemistry.

3. Open-Source Formulas
   We publish complete formulas publicly. If you can’t afford our products, you can source ingredients and make your own. Simpson gave oil away and taught people to make it; we adapted that ethos for today’s marketplace.

4. Evidence-Informed, Not Evidence-Overstating
   Our GENERAL KNOWLEDGE section (see below) represents our commitment to honest education. Simpson operated without peer-reviewed literature; we have that access and use it to distinguish what’s well-supported from what’s emerging or overstated.

Media Recognition: Seven ABC13 Features, Four Years

Between September 2019 and April 2023, ABC13 Houston featured Colin Valencia in seven news segments spanning business, law, medicine, community health, and politics. Five different reporters sought him out. No other Houston cannabis operator matches this frequency or breadth.

Feature Timeline:

1. September 15, 2019: “Texas CBD businesses booming”—Colin’s foundational quote: “I’m not trying to sell people snake oil…”
2. March 22, 2021: “Entrepreneur creates direct-to-consumer business”—”Pain comes in a lot of different forms”
3. May 24, 2021: “What is Delta 8 THC”—”Maybe you want to get high” (iconic honesty)
4. August 20, 2021: “Houston CBD shop giving away free products for COVID vaccine”—$35,000 product donation, city coordination
5. October 19, 2021: “Texas ban over Delta 8″—Colin proactively removed products, warned other operators
6. October 7, 2022: “Biden marijuana pardon”—Revealed Colin’s personal cannabis conviction history
7. April 21, 2023: “Marijuana industry getting creative”—”Right now is a Renaissance…”

This media record—seven features across four years, five reporters, multiple topics—cannot be purchased. It can only be earned. That credibility transfers to Brown County, even though we’re based in Houston.

GENERAL KNOWLEDGE: Complete Evidence Profiles

Research Method and Evidence Weighting

We prioritize: human clinical evidence → systematic reviews → NIH/institutional summaries → preclinical literature. This matters because the evidence base is uneven. CBD and delta-9 THC have the strongest human data; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes rely more on reviews, animal work, and early translational literature [1]-[29].

Institutional Baseline from NIH

• NCCIH: Strongest evidence is for rare epilepsies (CBD), chemo nausea/vomiting (THC), and HIV/AIDS appetite. Modest evidence for chronic pain and MS symptoms. Many other uses remain early-stage [1].
• FDA: Has not approved the cannabis plant itself. Only purified CBD (Epidiolex) and synthetic THC analogues (dronabinol/nabilone) have specific approvals [1].
• Safety Concerns: Impairment, motor vehicle crash risk, cannabis use disorder, pregnancy concerns, contamination/labeling inaccuracy, THC-vape lung injury [1].

CANNABINOID PROFILES

CBD (Cannabidiol)

• Evidence: Strongest human evidence in this formula. Best support for seizure disorders [1][2].
• Anxiety: 2024 systematic review (316 participants across 8 studies) showed significant anxiolytic signal, but authors stress limited clinical sample [3].
• Pain: 2024 systematic review found promising but heterogeneous literature [4].
• Sleep: 2023 insomnia review found methodologically weak literature [5].
• Safety: 2023 review found liver enzyme elevation and possible drug-induced liver injury, especially concerning for concentrated oral products and polypharmacy [6]. NCCIH flags diarrhea, sleepiness, appetite changes, mood effects, liver abnormalities, drug interactions [1].
• Bottom Line: Most evidence-developed nonintoxicating cannabinoid, but strong evidence concentrated in specific indications, not broad wellness claims [1]-[6].

CBG (Cannabigerol)

• Evidence: Mostly review-level and preclinical; human evidence sparse [7][8].
• Pharmacology: Biosynthetic precursor to major cannabinoids. Interacts with cannabinoid receptors, alpha-2 adrenoceptors, 5-HT1A signaling—mechanistically interesting but not clinically established [7].
• Research Areas: Neurologic disorders, inflammatory bowel disease, antibacterial activity—primarily pharmacology-led hypotheses or preclinical [7][8].
• Caution: 2021 review notes CBG is already sold commercially while evidence base remains thin [7].
• Bottom Line: Promising minor cannabinoid with limited clinical validation [7][8].

Delta-8 THC

• Evidence: Pharmacologically relevant, psychoactive, less clinically characterized than delta-9 THC [9]-[11].
• Comparative Pharmacology: 2022 review concluded delta-8 and delta-9 have broadly similar pharmacokinetic/pharmacodynamic behavior. Delta-8 is partial CB1 agonist, less potent than delta-9, likely due to weaker CB1 affinity [9].
• Public Health: 2023 scoping review found evidence base dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong human trials. Noted adverse consequence reports and regulatory/product-quality concerns [10].
• Manufacturing: 2024 chemistry review notes commercial delta-8 interest tied to greater stability and easier synthesis relative to naturally scarce plant levels, which creates product-byproduct and lab-testing questions [11].
• Bottom Line: Psychoactive THC analogue with real pharmacologic activity, incomplete human safety characterization, and manufacturing-quality uncertainty [9]-[11].

THCa (Tetrahydrocannabinolic Acid)

• Evidence: Important chemically/formulation-wise, but low on direct human therapeutic evidence [12].
• What It Is: Acidic precursor to THC; may represent large share of THC-related content in raw plant material. Decarboxylates to THC during heating/storage/processing [12].
• Psychoactivity: THCa itself does not produce psychoactive effects, but distinction only holds if molecule stays acidic and isn’t substantially decarboxylated [12].
• Research: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities—not equivalent to established human outcomes [12].
• Bottom Line: Highly relevant precursor whose interpretation depends heavily on route, temperature, processing, storage. Any claim must account for possible THC conversion [12].

Delta-9 THC

• Evidence: Strongest human evidence of psychoactive cannabinoids listed, but also clearest adverse-effect burden [1][13]-[15].
• Institutional Support: NCCIH identifies THC-containing medicines relevant to chemo nausea/vomiting, HIV/AIDS appetite/weight loss, some MS/pain outcomes, while stressing many other uses remain uncertain [1].
• Pain: 2022 systematic review found high-THC or comparable THC:CBD products may provide short-term pain benefit but increase dizziness, sedation, nausea, and treatment discontinuation due to adverse events [13].
• Pharmacokinetics: Inhaled THC: effects within seconds-minutes, peak 15-30 minutes, taper over hours. Oral THC: later onset, later peak, longer duration—matters for benefit and overconsumption risk [14].
• Mental Health Risk: 2025 systematic review of high-concentration THC products found consistent unfavorable associations with psychosis/schizophrenia outcomes and cannabis use disorder, plus concerning anxiety/depression signals in nontherapeutic settings [15].
• Broader Safety: Anxiety/panic at high doses, tachycardia, blood pressure changes, dependency potential, withdrawal, pregnancy concerns, accidental pediatric exposure, vape-related lung injury concerns [1][14][15].
• Bottom Line: Legitimate therapeutic relevance in some settings, but carries clearest intoxication, psychiatric, and dose-related safety liabilities [1][13]-[15].

CBN (Cannabinol)

• Evidence: Weak human evidence; marketing moved ahead of data [12][16][17].
• Marketing vs. Reality: Reputation for sleep/sedation widespread, but clinical support far thinner than market suggests [16][17].
• Sleep Research: 2021 narrative review screened 99 human-study abstracts, reviewed 8 full-text articles, found no clinical trials using validated sleep questionnaires or polysomnography to substantiate strong sleep-promoting claims [16].
• Broader Sleep Literature: 2024 updated review concluded cannabinoid sleep research still doesn’t match real-world use scale, with need for better-designed, adequately powered trials [17].
• Chemical Context: THC can degrade toward CBN under certain conditions, explaining why CBN is often discussed in aging/oxidized cannabis contexts [12].
• Bottom Line: One of clearest examples where cultural reputation exceeds current clinical evidence base [16][17].

CBC (Cannabichromene)

• Evidence: Emerging, intriguing, overwhelmingly preclinical or review-based [18][19].
• Pharmacology: 2024 focused review argues CBC has distinct pharmacodynamics, pharmacokinetics, receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, anti-seizure as especially interesting research targets [18].
• Older Literature: Anti-inflammatory effects, reduced gut hypermobility, modest rodent analgesic activity, possible neurobiological/antiproliferative relevance—but not strong evidence for patient-facing claims [19].
• Safety Caution: 2024 CBC review explicitly notes over-the-counter CBC products already sold despite little evidence establishing clinical efficacy or safety [18].
• Bottom Line: Scientifically credible minor cannabinoid deserving more research, not already-validated clinical active [18][19].

TERPENE PROFILES

Limonene

• Evidence: Largely review and preclinical, useful safety literature [20]-[22].
• Potential Activity: 2021 review describes multifunctional monoterpene with antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory possibilities—but overwhelming share from nonhuman/non-cannabis literature [21].
• Safety: Limonene oxidation products (hydroperoxides) are clinically relevant contact allergens important in patch-testing [22].
• Bottom Line: Biologically active, widely discussed, but cannabis-specific therapeutic claims should stay conservative unless directly human-supported [20]-[22].

Myrcene

• Evidence: Mostly preclinical, very limited human evidence [20][23].
• Research: 2021 review describes anxiolytic, antioxidant, anti-inflammatory, analgesic properties, possible mechanisms, but explicitly states human studies lacking [23].
• Interpretation Caution: Often invoked as proven sedative explaining couch-lock—stronger claim than human evidence supports [20][23].
• Bottom Line: Plausible bioactive terpene, but compound-specific clinical claims about mood, pain, sedation remain far ahead of definitive human proof [23].

Caryophyllene

• Evidence: Among most mechanistically interesting due to direct cannabinoid-system relevance, but still mostly preclinical [24].
• Distinctive Feature: 2021 review describes beta-caryophyllene as selective CB2 receptor agonist—unusual, making it especially relevant pharmacologically [24].
• Research Themes: Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective—human clinical confirmation limited [24].
• Bottom Line: Strongest candidate for terpene with cannabinoid-system significance, but shouldn’t be described as clinically proven for outcomes commonly attributed [24].

Pinene

• Evidence: Promising preclinical literature, weak human clinical confirmation [20][25].
• Brain Health Framing: 2021 review found antioxidant, anti-inflammatory, neuroprotective signals justifying future study, but emphasized evidence mostly preclinical and well-designed clinical trials lacking [25].
• Interpretation Caution: Claims that pinene reliably improves memory, sharpens attention, or counterbalances THC cognitive effects remain interesting hypotheses, not settled clinical facts [20][25].
• Bottom Line: Deserves scientific attention, but strong cognition-related claims should be presented as exploratory [25].

Linalool

• Evidence: Substantial preclinical interest, limited direct clinical confirmation [20][22][25][26].
• Research Summary: Repeatedly discussed regarding stress, mood, brain-health pharmacology. 2021 brain-health review found enough preclinical signal to justify continued investigation, while still emphasizing lack of robust human trials [25].
• Additional Literature: Separate review discusses possible antidepressant mechanisms and neuropharmacologic relevance, but remains translational rather than definitive clinical story [26].
• Safety: Oxidized linalool hydroperoxides recognized allergens in dermatitis literature [22].
• Bottom Line: Scientifically credible bioactive terpene, but current evidence supports cautious phrasing rather than firm therapeutic promises [22][25][26].

Humulene

• Evidence: Translationally interesting, but still early [20][27].
• Scoping Review: 2024 review analyzed 340 articles, found broad preclinical evidence for anti-inflammatory and other biologic effects, some rodent work suggesting cannabimimetic properties via CB1 and adenosine A2a pathways [27].
• Interpretation Caution: Findings valuable for hypothesis generation, but do not yet establish consistent human efficacy across pain, inflammation, or mood outcomes [27].
• Bottom Line: One of more interesting terpene research targets, but remains far from clinically settled [27].

Terpinolene

• Evidence: One of least clinically characterized terpenes in this file [20][28].
• Systematic Review: 2021 review screened 2,449 records, included 57 studies, concluded terpinolene has range of reported biological effects but evidence base still dominated by in silico, in vitro, and animal studies rather than human trials [28].
• Interpretation Caution: Even recent cannabis entourage reviews frame terpene benefits as exploratory, not established compound-specific clinical effects [20].
• Bottom Line: Biologically interesting, but among listed terpenes remains especially underdeveloped clinically [20][28].

Research Limits and Interpretation

• Evidence base highly uneven. CBD and delta-9 THC support most detailed human-facing statements; rest require more caution [1]-[29].
• Whole-cannabis extract data, purified-molecule data, semisynthetic cannabinoid data, terpene-only data are not interchangeable. Common writing error: letting evidence from one category stand in for another.
• Minor cannabinoids and terpenes commercially interesting precisely because underexplored, but claims often become inflated.
• Product quality matters as much as molecule identity. Labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent pharmacokinetics all materially affect interpretation in real-world products [1][10][11][14].
• For THCa particularly, chemistry is destiny: storage and heating can change actual exposure profile by converting acidic cannabinoids into neutral cannabinoids like THC [12].

Common Overstatements to Avoid

• Overstatement: CBN is clinically proven sleep cannabinoid.
  More Accurate: Specific sleep evidence for CBN remains weak and dated, with no strong validated-trial base yet identified [16][17].
• Overstatement: Myrcene is proven human sedative that reliably explains couch-lock.
  More Accurate: Myrcene has plausible preclinical bioactivity, but direct human proof for that common claim is limited [20][23].
• Overstatement: Terpenes in general have proven entourage effects in patients.
  More Accurate: Entourage hypotheses influential and worth studying, but robust clinical proof remains limited and highly compound-specific [20][29].
• Overstatement: THCa is always nonpsychoactive.
  More Accurate: THCa itself is not THC, but heating and processing can convert THCa into THC, changing effective exposure [12].
• Overstatement: Delta-8 THC is safe because it is hemp-derived.
  More Accurate: Delta-8 THC is psychoactive, pharmacologically close to delta-9 THC, and often entangled with manufacturing and testing concerns [9]-[11].

Practical Takeaways for Our Formulas

• Most evidence-developed actives: CBD and delta-9 THC.
• Delta-8 THC is not trivial or purely mild ingredient; it is psychoactive cannabinoid with less robust safety and efficacy characterization than delta-9 THC.
• THCa meaningfully changes with processing; should not be interpreted same way in raw, gently handled, and heated formats.
• CBG, CBN, CBC scientifically credible but clinically immature compared to CBD and THC.
• Listed terpenes likely highly relevant to aroma, flavor, potentially some biologic activity, but compound-specific human therapeutic claims should be made carefully and only where directly supported.

Complete Reference List [1]-[29]

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.

References for Rick Simpson Section:
RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.
RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005.
RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.
RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.
RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.
RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ)—Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

OilWell Cannabis is not a medical provider. This content is for educational purposes only. All products are for adult use (21+). Keep out of reach of children. Consult a healthcare professional before use, especially if pregnant, nursing, have a medical condition, or take medications. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Individual results may vary. Buyer assumes all responsibility for compliance with local laws.

OilWell Cannabis, LLC | 810 Richmond Avenue, Houston, TX 77006 | (832) 416-2816 | [email protected]

For Brown County residents ready to explore RSO: Order Now | View Complete RSO Guide